产品
编 号：F341534
分子式：C20H26O3
分子量：314.42
分子式：C20H26O3
分子量：314.42
产品类型
规格
价格
是否有货
结构图
CAS No: 37905-07-0
产品详情
生物活性：
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells.
体内研究：
Jolkinolide A (40 mg/kg; 腹腔注射; 每 3 天一次，持续 2 个月) 抑制小鼠A549细胞异种移植瘤模型中VEGF蛋白的表达。Animal Model:Female BALB/c nude mice (4-5 weeks old) injected with A549 cells
Dosage:40 mg/kg
Administration:Intraperitoneal injection; once every 3 days for 2 months
Result:Significantly inhibited the expression of VEGF protein on the first, 10th, 30th, 45th, and 60th day of administration.
体外研究：
Jolkinolide A (20-100 μg/mL; 24 h) 提高 A549 细胞中 caspase-9 蛋白水平。Jolkinolide A (40-80 μg/mL; 24 h) 降低 A549 细胞中 Akt-STAT3-mTOR 蛋白的表达。Jolkinolide A (20-100 μg/mL; 24 h) 抑制人脐静脉内皮细胞 (HUVEC) 增殖和迁移，促进细胞凋亡。
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells.
体内研究：
Jolkinolide A (40 mg/kg; 腹腔注射; 每 3 天一次，持续 2 个月) 抑制小鼠A549细胞异种移植瘤模型中VEGF蛋白的表达。Animal Model:Female BALB/c nude mice (4-5 weeks old) injected with A549 cells
Dosage:40 mg/kg
Administration:Intraperitoneal injection; once every 3 days for 2 months
Result:Significantly inhibited the expression of VEGF protein on the first, 10th, 30th, 45th, and 60th day of administration.
体外研究：
Jolkinolide A (20-100 μg/mL; 24 h) 提高 A549 细胞中 caspase-9 蛋白水平。Jolkinolide A (40-80 μg/mL; 24 h) 降低 A549 细胞中 Akt-STAT3-mTOR 蛋白的表达。Jolkinolide A (20-100 μg/mL; 24 h) 抑制人脐静脉内皮细胞 (HUVEC) 增殖和迁移，促进细胞凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备